Merit Medical Raises 2026 Outlook Amid $140 M Acquisition and DualCap Divestiture
Merit Medical Systems (NASDAQ:MMSI) lifted its full‑year 2026 revenue guidance to $1.612‑$1.634 billion and nudged non‑GAAP EPS to $4.01‑$4.15, while completing a $28 million DualCap divestiture and a $140 million purchase of View Point Medical.
Merit Medical’s Q1 2026 earnings beat expectations and set a more aggressive full‑year trajectory. Reported revenue rose 7% YoY to $381.9 million, with constant‑currency sales up 5% and organic growth of 3% after stripping out the DualCap sale. The company re‑classified its top line into Foundational ($255.5 million, +6%) and Therapeutic ($126.4 million, +10%) segments, underscoring a faster‑growing oncology portfolio.
Operating profitability also improved. GAAP operating margin ticked up to 11.6% and non‑GAAP margin to 19.7%, while GAAP EPS surged 39% to $0.68 and non‑GAAP EPS rose 9% to $0.94. Free cash flow jumped 26% to $24.7 million, reflecting tighter working‑capital management.
Strategically, Merit closed two pivotal transactions in Q1. On Feb. 17, it sold the DualCap® product line to Health Line International for $28 million, receiving $25.5 million in cash at closing. The divestiture cleans up the portfolio and funds the next move: a $140 million acquisition of View Point Medical, completed Apr. 1. The deal, funded with $90 million cash, adds the OneMark® Detection Imaging System and tissue markers, expanding Merit’s therapeutic oncology offering. Management projects the acquisition will contribute $2‑$4 million of incremental revenue for FY 2026, with a modest $0.05 per‑share EPS dilution and a $2 million hit to interest income.
With the transactions settled, Merit updated its guidance. Full‑year 2026 revenue is now expected between $1.612 billion and $1.634 billion (6‑8% YoY growth), and non‑GAAP EPS between $4.01 and $4.15 (5‑8% growth). The company’s balance sheet remains robust: cash and equivalents rose to $488.1 million, total debt sits at $747.5 million, and borrowing capacity remains near $697 million.
Investors responded positively; the stock climbed 5.15% to $68.18 on the day of the filing, outpacing the S&P 500’s 1.08% gain. Analysts cited the stronger guidance and the strategic fit of OneMark as catalysts for continued upside, while noting the modest EPS dilution.
Merit will field questions in an earnings call on Apr. 30 at 4:30 p.m. ET, with a webcast and slide deck posted on merit.com.
Forward‑looking statements in this release are subject to risks, including integration of the View Point acquisition and market acceptance of the expanded therapeutic portfolio.
Financial Details
| Q1 2026 Reported Revenue Millions | 381.90 |
| Q1 2026 Revenue Growth Percent | 7% |
| Q1 2026 Constant Currency Revenue Growth Percent | 5% |
| Q1 2026 Organic Constant Currency Revenue Growth Percent | 3% |
| Q1 2026 Foundational Revenue Millions | 255.48 |
| Q1 2026 Foundational Growth Percent | 6% |
| Q1 2026 Therapeutic Revenue Millions | 126.40 |
| Q1 2026 Therapeutic Growth Percent | 10% |
| GAAP Operating Margin Percent | 11.6% |
| Non GAAP Operating Margin Percent | 19.7% |
| GAAP EPS | 0.68 |
| GAAP EPS Growth Percent | 39% |
| Non GAAP EPS | 0.94 |
| Non GAAP EPS Growth Percent | 9% |
| Free Cash Flow Millions | 24.70 |
| Free Cash Flow Growth Percent | 26% |
| Divestiture Proceeds Cash Millions | 25.50 |
| Divestiture Total Price Millions | 28 |
| Acquisition Total Price Millions | 140 |
| Acquisition Cash Paid Millions | 90 |
| GAAP Gross Margin Percent | 48.4% |
| Non GAAP Gross Margin Percent | 53.2% |
| GAAP Net Income Millions | 41.00 |
| Non GAAP Net Income Millions | 56.70 |
| Cash and Cash Equivalents Millions | 488.10 |
| Total Debt Millions | 747.50 |
| Borrowing Capacity Millions | 697 |
| Full Year 2026 Revenue Guidance Low Billion | 1.61 |
| Full Year 2026 Revenue Guidance High Billion | 1.63 |
| Full Year 2026 Revenue Growth Guidance Percent Low | 6% |
| Full Year 2026 Revenue Growth Guidance Percent High | 8% |
| Full Year 2026 Non GAAP EPS Guidance Low | 4.01 |
| Full Year 2026 Non GAAP EPS Guidance High | 4.15 |
| Full Year 2026 Non GAAP EPS Growth Guidance Percent Low | 5% |
| Full Year 2026 Non GAAP EPS Growth Guidance Percent High | 8% |
| Acquisition Projected Revenue Increment Millions Low | 2 |
| Acquisition Projected Revenue Increment Millions High | 4 |
| Acquisition EPS Dilution Per Share | -0.05 |
| Acquisition Interest Income Reduction Millions | 2 |
| Acquisition Non Cash Expenses Millions | 5.30 |
Key Takeaways
- Full‑year 2026 revenue guidance raised to $1.612‑$1.634 billion; non‑GAAP EPS to $4.01‑$4.15.
- Completed $28 million DualCap divestiture and $140 million acquisition of View Point Medical, adding OneMark oncology platform.
- Q1 revenue up 7% YoY to $381.9 million; GAAP EPS $0.68 (+39% YoY), non‑GAAP EPS $0.94 (+9%).
- Free cash flow surged 26% to $24.7 million; cash balance $488.1 million, debt $747.5 million.
- Shares jumped 5.15% to $68.18 on the news, outperforming the broader market.